Project Grant R01HL183390
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $530K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $172,720 to the Regents of the University of Michigan on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund a five-year Project Grant investigating neutrophil mitophagy in antiphospholipid syndrome. The research evaluates how dysfunctional mitochondrial autophagy alters neutrophil metabolism to promote pathogenic neutrophil extracellular trap release in...
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $2,257,845 under a Project Grant (R01HL180433) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a real-time, non-invasive micro-rheology technique to characterize aging thrombi using ultrasound-responsive nanodroplets. The nanodroplets phase-transition into microbubbles when exposed to focused ultrasound above a threshold amplitude—a...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $173,012 on February 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of 12-lipoxygenase in regulating eicosapentaenoic acid (EPA) effects on platelet activation and thrombosis. The research uses pharmacological and genetic techniques to determine how peroxisome proliferator-activated receptors and gas-coupled G protein–coupled receptors regulate the...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define mechanisms for induction of antibacterial lung-resident CD4 T cells. The project will run through April 19, 2029, with performance in Ann Arbor, Michigan. The research addresses how Streptococcus pneumoniae drives the formation of CD4+ tissue-resident memory (TRM) cells in the lungs. Current...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $1,026,853 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the molecular basis of thrombospondin-1-induced fibro-fatty diaphragm remodeling as a driver of obesity-associated respiratory dysfunction. The research investigates how diet-induced obesity promotes diaphragm weakness through fibro-adipogenic progenitor cell expansion and extracellular...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the role of Toll-like Receptor-9 (TLR9) in type II epithelial cells and fibroblasts during influenza and Staphylococcus aureus coinfection. The research addresses the mechanism by which TLR9 expression in lung structural cells contributes to poor outcomes during influenza-bacterial...
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $1,119,666 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate compartmentalized G protein-coupled receptor signaling in cardiac function. The award funds research into how beta-1 and beta-2 adrenergic receptors and angiotensin-1 receptors signal from different intracellular compartments to regulate distinct cardiac cell functions. The project examines the...